Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

SGLT2 inhibitors: are they safe?

Sebastian Filippas-Ntekouan1, Theodosios D Filippatos1, Moses S Elisaf1

  • 1a Department of Internal Medicine, School of Medicine , University of Ioannina , Ioannina , Greece.

Postgraduate Medicine
|October 18, 2017
PubMed
Summary

Sodium-glucose linked transporter type 2 (SGLT2) inhibitors offer cardiovascular and kidney benefits for diabetes management. While generally safe, potential risks include urogenital infections and, rarely, other adverse events requiring careful patient selection and monitoring.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolically healthy obesity is independently associated with 20-year incidence of cardiovascular disease: findings from the ATTICA cohort study (2002-2022).

International journal of obesity (2005)·2026
Same author

One-Hour Post-Load Glucose Is Associated with Multisystem Complications in People Living with Obesity.

Biomolecules·2026
Same author

Incidence, Risk Factors, and Outcomes of Thrombocytopenia in Older Medical Inpatients: A Prospective Cohort Study.

Hematology reports·2024
Same author

Pathophysiological Mechanisms and Clinical Associations of Non-Alcoholic Fatty Pancreas Disease.

Diabetes, metabolic syndrome and obesity : targets and therapy·2024
Same author

Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease.

Biomedicines·2023
Same author

GLP-1 analogs and regional adiposity: A systematic review and meta-analysis.

Obesity reviews : an official journal of the International Association for the Study of Obesity·2023

Area of Science:

  • Endocrinology
  • Nephrology
  • Cardiology

Background:

  • Sodium-glucose linked transporter type 2 (SGLT2) inhibitors are a novel class of antidiabetic medications.
  • These drugs demonstrate beneficial effects on cardiovascular and renal outcomes.

Purpose of the Study:

  • To review and present the safety profile of SGLT2 inhibitors.
  • To identify and discuss potential adverse events associated with SGLT2 inhibitor use.

Main Methods:

  • Literature review focusing on safety data from clinical trials and post-marketing surveillance.
  • Analysis of reported adverse events, including infections, renal effects, and other complications.

Main Results:

  • Urogenital infections are the most common side effects, typically mild to moderate.
Keywords:
SGLT2 inhibitorsadverse effectsamputationcancerelectrolyteskidney

Related Experiment Videos

  • Caution is advised in volume-depleted patients or those on nephrodynamic-affecting drugs.
  • Specific concerns include amputation and fracture risks with canagliflozin, and rare euglycemic diabetic ketoacidosis.
  • No increased hypoglycemia risk, but dose adjustments for sulfonylureas may be needed.
  • Malignancy risk is not definitively linked, but caution is advised in specific patient groups.

    • Conclusions:

    • SGLT2 inhibitors appear safe and effective for diabetes treatment, with notable cardiovascular and kidney benefits.
    • Long-term safety data are still accumulating.
    • Careful patient selection and monitoring are essential to mitigate potential risks.